spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  N-methyl-D-aspartate 

 HSMN NewsFeed - 7 Aug 2023
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Jan 2020
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 20 Dec 2019
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Aug 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jul 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 27 Dec 2017
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 Dec 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Oct 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Sep 2017
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2017
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Jun 2017
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2017
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Sep 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 10 May 2016
Aptinyx Raises $65 Million in Series A Financing to Advance Therapies for Neurological Disorders
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 5 Oct 2015
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2015
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Dec 2013
Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2012
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2007
Javelin Pharmaceuticals Announces Peer-Reviewed Publication of Successful Postoperative Pain Trial with PMI-100/150 (Intranasal Ketamine) in International Journal, ''Acute Pain''
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Jan 2007
Javelin Pharmaceuticals Announces Results of FDA Meeting for Nasal Ketamine
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation
Return to NewsFeed  

 Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 23 additional stories matching:
N-methyl-D-aspartate
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!